19:38 IST
BSE
Results Update
Jagsonpal Pharmaceuticals Results Update
Jagsonpal Pharmaceuticals reported FY26 revenue of ₹287.2 Crore, a 7% YoY increase, with PAT rising 19% to ₹44.6 Crore. The Board approved a ₹40 Crore share buyback at ₹250 per share and proposed a 200% dividend. Growth was driven by strong demand in core therapies like Gynaecology and Orthopaedics.
- Value
- ₹287.2 Cr